Skip to main content
OpenTrials
Completed

NCT Number: NCT00449943

Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)

Cardiovascular disease and ischemic heart disease is the #1 killer in Canada. Currently, Cardiac invasive catheterization angiography (CICA) is the gold standard for the assessment of the arteries in the heart. However, cardiac catheterization has risks which prohibit its use in all patients. These risks include: death, heart attack, stroke and bleeding. Cardiac computed tomography angiography (CTA) is a new non-invasive technology which may enable the evaluation of patients' coronary anatomy without exposing patients to the risks of invasive cardiac catheterization.

The purpose of this project is to compare CT angiography (CTA) to Tc-99m single photon emission computed tomography (Tc-99m SPECT)

We will enroll patients who are waiting for a CICA or who have been referred for a TC-99m SPECT or CTA scans at the University of Ottawa Heart Institute. Consenting patients who are waiting for a CICA will have both a CTA and a Tc-99m SPECT scan. Consenting patients referred for a CTA or Tc-99m SPECT will have both the CTA and Tc-99m SPECT in a random order but not CICA (unless ordered by your physician).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients referred for Tc-99m SPECT or CTA; or
  • Patients referred for CICA without preceding (< 12 months) MPI or CTA

Exclusion criteria

  • Previous revascularization (PCI or CABG)
  • Age < 18 years or lack of consent
  • Renal Insufficiency (GFR < 60 ml/min)
  • Allergy or contraindication to contrast agent or dipyridamole
  • Refractory angina requiring urgent/emergent coronary angiography
  • Contraindication to radiation exposure (e.g. pregnancy)
  • Uncontrolled HR
  • Atrial fibrillation, frequent atrial or ventricular ectopy (> 1/minute)
  • Unable to perform 10 second breath-hold

Treatment and study plan

Computed Tomographic Angiography

Procedure

CT scan

Myocardial Perfusion Imaging Scan

Procedure

SPECT

Primary outcomes

  1. To measure the accuracy of CTA to SPECT for the diagnosis of CAD

    Time frame: 1 year

Secondary outcomes

  1. To examine the accuracy of CTA predicting the mode of treatment: Medical therapy or revascularization (PCI versus CABG)

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Ottawa Heart Institute Research Corporation

Other

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2010
First posted
Mar 21, 2007
Registry last updated
Jan 26, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.